Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trovafloxacin 是广谱喹诺酮类抗生素,对革兰氏阳性,革兰氏阴性和厌氧菌有活性。它可阻断 DNA 促旋酶 和拓扑异构酶 IV 的活性。它也是口服活性的 Pannexin 1通道选择性抑制剂,对 PANX1内向电流的 IC50为 4 μM。
产品描述 | Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive. |
靶点活性 | Pannexin 1 channel (PANX1):4 μM (IC50) |
体外活性 | In HepG2 cells, Trovafloxacin (20 μM; 24 hours; ) and tumor necrosis factor (TNF; 4 ng/mL) incubation induces apoptosis and increases leakage of lactate dehydrogenase (LDH)[1]. Trovafloxacin (20 μM; 24 hours; HepG2 cells) and TNF (4 ng/mL) incubation increases expression of early NF-κB-related factors A20 and IκBα[1]. Trovafloxacin prolongs TNF-induced activation of MAPKs and IKKα/β activation in HepG2[1]. Trovafloxacin is a potent TO-PRO-3 uptake inhibitor by apoptotic cells. Trovafloxacin also inhibits ATP release from apoptotic cells. Trovafloxacin is equally active against both penicillin-susceptible and -resistant pneumococci, with MICs of 0.06-0.25 mg/mL reported for more than 700 isolates. The MICs of Trovafloxacin at which 90% of isolates are inhibited for 55 isolates of pneumococci is 0.125 μg/mL[3]. |
体内活性 | In male C57BL/6 J mice, TNF-induced p65 nuclear translocation disrupted by Trovafloxacin (150 mg/kg; oral administration). Trovafloxacin treatment increases expression of early NF-κB-related factors A20 and IκBα[1]. Trovafloxacin increased serum levels of alanine amino transferases (ALT) and pro-inflammatory cytokines when administered in combination with lipopolysaccharide (LPS) or TNF to mice induces severe liver toxicity associated with vast apoptotic areas in the liver[1]. |
分子量 | 416.35 |
分子式 | C20H15F3N4O3 |
CAS No. | 147059-72-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 4.16 mg/ml (10 mM), Sonification is recommended
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4018 mL | 12.0091 mL | 24.0183 mL | 60.0456 mL |
5 mM | 0.4804 mL | 2.4018 mL | 4.8037 mL | 12.0091 mL | |
10 mM | 0.2402 mL | 1.2009 mL | 2.4018 mL | 6.0046 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Trovafloxacin 147059-72-1 DNA Damage/DNA Repair Microbiology/Virology DNA gyrase Topoisomerase Antibacterial Antibiotic NF-κB inhibit PANX1 DNA gyrase LPS pro-inflammatory hepatotoxicity topoisomerase-IV Inhibitor pneumococci Bacterial broad-spectrum TNF inhibitor